Recurrent Coronary Artery Vasospasm Complicated by Cardiac Arrests in Heart Transplant Recipient: An Unusual Enemy
Andrea Tedeschi,Umberto Ianni,Piero Gentile,Matteo Palazzini,Gabriella Masciocco,Enrico Ammirati,Andrea Garascia
DOI: https://doi.org/10.1097/tp.0000000000004975
2024-05-31
Transplantation
Abstract:Vasospastic angina, defined as symptomatic epicardial coronary artery vasoconstriction, is a condition potentially leading to acute coronary syndromes and ventricular arrhythmias. 1 Although this phenomenon is rare in heart transplant (HT) recipients, asymptomatic coronary vasospasm (CV) may be observed during routine coronary angiography, 2 serving as a potential marker of poor prognosis in this population. 3 A single case of multiple cardiocirculatory arrests due to recurrent CV in an HT recipient was described. 4 We present the case of a 30-y-old male who underwent HT in 2007 for dilatative cardiomyopathy. He was treated with tacrolimus and mycophenolate mofetil and had no significant rejection or coronary artery disease (CAD) demonstration during routine angiography conducted at 1, 5, and 10 y posttransplant. In December 2020, he presented a cardiocirculatory arrest preceded by chest pain. Since postresuscitation electrocardiogram showed ST-segment elevation in inferior leads, emergent coronary angiography was performed demonstrating diffuse spasm of the right coronary artery (Figure 1A) with complete resolution after intracoronary nitroglycerin administration (Figure 1B). Endomyocardial biopsy indicated no cellular rejection, while cardiac magnetic resonance showed diffuse edema of interventricular septum and anterolateral wall in T2-weighted sequences, consistent with acute rejection. Moreover, the finding of high titer of major histocompatibility complex class 2 donor-specific antibodies (DSAs), led to prompt treatment for antibody-mediated rejection with steroids and plasmapheresis, followed by immunoglobulin infusion. Finally, implantable cardiac defibrillator was placed, and treatment with nifedipine was instituted. In August 2021, the patient was hospitalized after an appropriate implantable cardiac defibrillator shock for ventricular fibrillation with prodromal angina. The coronary angiography identified diffuse CV and after nitrates administration, critical stenosis of the proximal right coronary artery was pointed out and a percutaneous coronary intervention was performed. Endomyocardial biopsy and DSAs assessment were both negative. The patient was discharged after the introduction of transdermic long-acting nitrate (nitroglycerin) and a switch from mycophenolate mofetil to everolimus to prevent further advancement of CAD. After 2 more episodes of acute coronary syndrome with CV demonstrated at coronary angiography without evidence of CAD progression, we decided to empirically treat the patient with steroid bolus and weekly photopheresis sessions, even in the absence of DSAs. A relief therapy with nebivolol was instituted and nifedipine was replaced with diltiazem. Despite this aggressive therapeutic management, a third CCA occurred in March 2022, prompting the reintroduction of patient to the HT waiting list. Several aspects make this case characteristic. Most CV episodes occur without any symptoms due to the denervated state of the heart posttransplant. The occurrence of chest pain in association with CV episodes suggests reinnervation occurred in our patient. 5 Traditional CV preventive medication proved ineffective in this case, raising questions about the underlying pathogenesis respect to healthy subjects. Furthermore, CAD progression documented after the second CCA suggests CV as an early manifestation of coronary allograft vasculopathy. 3 The hypothesis of pathological vasoreactivity in the donor's heart, compounded by factors like antibody-mediated rejection, is intriguing, yet purely speculative. On the other hand, DSAs normalization without symptom relief underscores the multifactorial nature of this phenomenon. Further researches are needed to explore underlying processes and develop effective therapies for this unique patient group.
immunology,surgery,transplantation